Danos Olivier

SEC source: 0001562180-25-003008 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,348

F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025.

SEC source: 0001562180-25-000189 · primarydocument.xml · derivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,721

Underlying: Common Stock · 95,721 shares

Expires 2035-01-02

F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-25-000189 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,800

F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028 and January 1, 2029 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-25-000189 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 172,453

F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024.

SEC source: 0001562180-24-006013 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,083

F3 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of February 1, 2025, August 1, 2025, February 1, 2026 and August 1, 2026 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-24-006013 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,216

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 28, 2024.

SEC source: 0001562180-24-000249 · primarydocument.xml · derivative · entry 5

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,050

Underlying: Common Stock · 61,050 shares

Expires 2034-01-02

F7 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-24-000249 · primarydocument.xml · nonDerivative · entry 4

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,853

F6 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-24-000249 · primarydocument.xml · nonDerivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,391

F5 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the Issuer's common stock on December 29, 2023.

SEC source: 0001562180-24-000249 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,801

F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2023 through June 30, 2023. This transaction is exempt under Rule 16b-3(c).

F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2023.

SEC source: 0001562180-23-000220 · primarydocument.xml · derivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,986

Underlying: Common Stock · 52,986 shares

Expires 2033-01-03

F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-23-000220 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,950

F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-23-000220 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,020

F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022.

SEC source: 0001562180-24-000249 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,678

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022.

SEC source: 0001562180-22-000156 · primarydocument.xml · derivative · entry 5

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,100

Underlying: Common Stock · 51,100 shares

Expires 2032-01-03

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-22-000156 · primarydocument.xml · nonDerivative · entry 4

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,078

F5 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-22-000156 · primarydocument.xml · nonDerivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,378

SEC source: 0001562180-22-000156 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,599

F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is exempt under Rule 16b-3(c).

F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2021.

SEC source: 0001562180-22-000156 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,598

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2021.

SEC source: 0001562180-21-000141 · primarydocument.xml · derivative · entry 4

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2031-01-04

F6 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-21-000141 · primarydocument.xml · nonDerivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,043

F5 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer.

SEC source: 0001562180-21-000141 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,443

F3 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is exempt under Rule 16b-3(c).

F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2020.

SEC source: 0001562180-20-000218 · primarydocument.xml · derivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-21-000141 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,802

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2019 through December 31, 2019. This transaction is exempt under Rule 16b-3(c).

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2019.

SEC source: 0001562180-19-002295 · primarydocument.xml · derivative · entry 4

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,500

Underlying: Common Stock · 2,000 shares

Expires 2027-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-19-002295 · primarydocument.xml · nonDerivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $52.94 to $53.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-002295 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $51.88 to $52.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-19-002295 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001562180-19-001906 · primarydocument.xml · derivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,500

Underlying: Common Stock · 5,000 shares

Expires 2027-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-19-001906 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-000220 · primarydocument.xml · derivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2029-01-03

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-18-004807 · primarydocument.xml · derivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,500

Underlying: Common Stock · 1,500 shares

Expires 2027-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-18-004807 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-18-004207 · primarydocument.xml · derivative · entry 6

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 20,000 shares

Expires 2027-03-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.

SEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 5

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F5 · price: This transaction was executed in multiple trades at prices ranging from $65.40 to $65.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 4

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $64.36 to $65.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 3

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,216

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades at prices ranging from $63.35 to $64.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 2

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $62.31 to $63.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-18-004207 · primarydocument.xml · nonDerivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0001562180-18-000240 · primarydocument.xml · derivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 41,250 shares

Expires 2028-01-03

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2019 while the optionee provides continuous service to the Issuer.

SEC source: 0000899243-17-008828 · doc4.xml · derivative · entry 1

Danos Olivier · CIK 0001701180 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2027-03-26

F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 3/27/2018 while the optionee provides continuous service to the Issuer.